Hematopoietic and Lymphoid Cell NeoplasmNCT05173961
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
A study testing Internet-Based Intervention and Survey Administration in people with Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by City of Hope Medical Center at 1 site in United States.
Trial summary
This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex. The technology, daily treatments, and possible side effects can be confusing to prevent and manage. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Internet-Based Intervention and Survey Administration
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2022to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 and older.
- Can read and speak English and provide informed consent.
- Diagnosed with cancer, any stage, any disease site.
- Must be consented to undergo a course of radiotherapy, starting within one month. No limits on duration of radiation apply. Patients must be consented prior to initiating radiotherapy, however.
- Has regular access to a mobile device.
- Note: This requirement unfortunately leads to the exclusion of underserved patients who cannot afford to have a mobile device. Given that the goal of this study is to establish feasibility of a mobile application, there are no true alternatives, given that these patients would require access to a mobile device if this app were commercially available. However, for impacted patients, the relevant application and resources will be made available on iPads they can access during treatment and a website they can access on any web-enabled device, to ensure they have access as much as reasonably possible. Future iterations of the application will aim to increase access to the resource however possible, but limitations will always apply due to how the core functionality of the app requires a mobile device.
Who cannot join
- Less than 18 years old.
- Non-English speaking.
- Inability to operate a mobile device.
Trial locations and contacts
1 site in 1 country.
United States1 site
City of Hope Medical Center
Duarte, California, 91010
About this study
Official title: Pilot Study of Mobile Application Designed to Assist Patients Undergoing Radiation Therapy
This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex. The technology, daily treatments, and possible side effects can be confusing to prevent and manage. Traditional radiation patient education includes a large amount of information, including details of treatment logistics, side effect prevention, and management. However, this information is not always readily accessible or memorable through the long course of therapy, and critical details can be missed. Oncpatient is a mobile application intended to be a more convenient and accessible form of patient education and guidance that is readily available to help patients and their caretakers navigate through radiation treatment.
Read the detailed description
PRIMARY OBJECTIVE:
- To determine the feasibility of implementing a mobile application designed to be an educational resource designed for patients undergoing radiation treatment.
SECONDARY OBJECTIVES:
- To assess patient opinions on the usability and helpfulness of the mobile application in helping them through radiation treatments.
II. To assess satisfaction with the mobile application and radiation treatment. III. To assess opinions on existing or new features for the mobile application to be given to future patients.
OUTLINE:
Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
- Being tested
- Internet-Based Intervention, Survey Administration
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Internet-Based InterventionOther
Use oncpatient mobile application
Survey AdministrationOther
Complete survey
| Study group | Role | What they receive |
|---|---|---|
| Supportive Care (oncpatient application, survey) | Experimental | Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment. Receives: Other: Internet-Based Intervention; Other: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Completion rate
The percent of patients who indicate in the survey that they were able to download the application and use it at least once during radiation will be defined as the completion rate.
Measured: Up to 1 year
Secondary outcomes (3)
Patient opinions on the usability and helpfulness of the mobile application in helping them through radiation treatments
Survey responses and collected demographic data will be evaluated with descriptive statistics where possible. Free-text responses will be recorded and utilized by the application developers to inform future iterations of the application.
Measured: Up to 1 year
Satisfaction with the mobile application and radiation treatment
Survey responses and collected demographic data will be evaluated with descriptive statistics where possible. Free-text responses will be recorded and utilized by the application developers to inform future iterations of the application.
Measured: Up to 1 year
Opinions on existing or new features for the mobile application to be given to future patients
Survey responses and collected demographic data will be evaluated with descriptive statistics where possible. Free-text responses will be recorded and utilized by the application developers to inform future iterations of the application.
Measured: Up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2021
- Study start1 Nov 2022
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- More trials run by City of Hope Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- City of Hope Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Colton Ladbury, Principal investigator, City of Hope Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05173961
- Sponsor's protocol ID
- 21564
- Other IDs
- NCI-2021-13835, 21564, P30CA033572
- Status last verified
- Oct 2026
- First submitted
- 27 Dec 2021
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study of Mobile Application Designed to Assist Patients Undergoing Radiation Therapy
- ClinicalTrials.gov ID
- NCT05173961
- Acronym / sponsor ID
- 21564
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (actual)
- Lead sponsor
- City of Hope Medical CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 1 Nov 2022 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 30 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex. The technology, daily treatments, and possible side effects can be confusing to prevent and manage. Traditional radiation patient education includes a large amount of information, including details of treatment logistics, side effect prevention, and management. However, this information is not always readily accessible or memorable through the long course of therapy, and critical details can be missed. Oncpatient is a mobile application intended to be a more convenient and accessible form of patient education and guidance that is readily available to help patients and their caretakers navigate through radiation treatment.
Detailed description
PRIMARY OBJECTIVE:
- To determine the feasibility of implementing a mobile application designed to be an educational resource designed for patients undergoing radiation treatment.
SECONDARY OBJECTIVES:
- To assess patient opinions on the usability and helpfulness of the mobile application in helping them through radiation treatments.
II. To assess satisfaction with the mobile application and radiation treatment. III. To assess opinions on existing or new features for the mobile application to be given to future patients.
OUTLINE:
Patients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Supportive Care (oncpatient application, survey) | Experimental | Other: Internet-Based Intervention, Other: Survey AdministrationPatients use the oncpatient mobile application over the course of radiation therapy. Patients also complete a survey on the final day of radiation treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 and older.
- Can read and speak English and provide informed consent.
- Diagnosed with cancer, any stage, any disease site.
- Must be consented to undergo a course of radiotherapy, starting within one month. No limits on duration of radiation apply. Patients must be consented prior to initiating radiotherapy, however.
- Has regular access to a mobile device.
Key exclusion criteria (3 listed)
- Less than 18 years old.
- Non-English speaking.
- Inability to operate a mobile device.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Internet-Based InterventionUse oncpatient mobile application | Other | Supportive Care (oncpatient application, survey) |
| Survey AdministrationComplete survey | Other | Supportive Care (oncpatient application, survey) |
Primary outcome
Completion rate
Time frame: Up to 1 year
The percent of patients who indicate in the survey that they were able to download the application and use it at least once during radiation will be defined as the completion rate.
3 secondary outcomes
Patient opinions on the usability and helpfulness of the mobile application in helping them through radiation treatments
Time frame: Up to 1 year
Satisfaction with the mobile application and radiation treatment
Time frame: Up to 1 year
Opinions on existing or new features for the mobile application to be given to future patients
Time frame: Up to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Colton Ladbury principal investigator
City of Hope Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Internet-Based Intervention and Survey Administration in people with Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by City of Hope Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Completion rate (time frame: Up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.